Severe psoriasis treated with a new macrolide: everolimus. - Wikidata - awgldk - TriplyDB

Severe psoriasis treated with a new macrolide: everolimus.

Severe psoriasis treated with a new macrolide: everolimus.

http://www.wikidata.org/entity/Q36708370

about

Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation.Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway.Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis.Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model.Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis.Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin.Severe atopic dermatitis treated with everolimus.TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin.Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

P2860

Q33897776-6FFBF39E-6C77-4CE4-BDA6-CC168E4D4CCA Q36425959-061E11F9-26BA-4D73-82A4-2DB37CF039FA Q38841006-8B54F7F0-D540-44BE-A327-553E0C9070D2 Q39413456-84CE30BA-773B-4276-9B23-7CF70569FFC9 Q41211068-130879A6-C989-48C2-9ADC-D4274FA77083 Q41884115-D1721A6D-96A3-443C-9239-4E1500AAD279 Q42520536-53356089-7838-48F2-A047-72AE0626F741 Q43232058-7F74482D-AC0B-4DF2-8361-1F767E93B11C Q48362769-41439B53-1469-4F81-BA81-77D6A9117B17 Q51653442-99F1610A-264B-4E1A-B729-E8917D46A84F

P2860

Severe psoriasis treated with a new macrolide: everolimus.

http://www.wikidata.org/entity/Q36708370

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Severe psoriasis treated with a new macrolide: everolimus.

@ast

Severe psoriasis treated with a new macrolide: everolimus.

@en

type

label

Severe psoriasis treated with a new macrolide: everolimus.

@ast

Severe psoriasis treated with a new macrolide: everolimus.

@en

prefLabel

Severe psoriasis treated with a new macrolide: everolimus.

@ast

Severe psoriasis treated with a new macrolide: everolimus.

@en

P1433

Q36708370-0DD5DAE8-D291-4130-95D1-09110350323D

P1476

Q36708370-5EE9905D-F8AA-431F-A518-62283FE37D21

P2093

Q36708370-0EC15AB9-F327-4AB5-A387-0CB6D503C965

Q36708370-257DA10F-4632-440A-A28E-4D23C356CAAC

Q36708370-A36E2E8F-4653-4416-BFF9-F1916674A31A

Q36708370-DACE8E70-4CBD-412A-9417-75E30046C0F4

Q36708370-E2F01BFB-D135-4223-A167-4980CFE4816C

Q36708370-F5669151-BCEE-40DF-99A6-5C0B6E20F6C9

P2860

Q36708370-3255F93B-DC7D-45E4-865D-CAE2898003C8

Q36708370-3947E2CB-9DC8-489A-8E2B-F7AECA0590AF

Q36708370-6836D92D-65FD-43F3-A25F-4A5AD968BF45

Q36708370-841BF4EF-A711-449A-9E77-75DAFDD7472E

Q36708370-8C3ABE97-8B85-40FD-94DB-59E09643F570

Q36708370-9A607FB3-64BD-41DA-A98C-4E6F75661D94

Q36708370-9C968DE4-79A3-4A71-91AA-D4D5C930DAFD

Q36708370-ACAC18FD-6AB4-4619-89F9-23F5B8A7E4F7

P304

Q36708370-36865D9E-415B-43AC-8410-7DB0BB6BED60

P31

Q36708370-BA7A9B83-C7E4-40BF-AFD8-373ACEB02164

P356

Q36708370-1E376A67-6001-4B07-A47D-D726BD5DF227

P407

Q36708370-CE8D17ED-0CFD-4182-8C2C-7A9A0BD09160

P433

Q36708370-91DC36D1-9E0A-4108-8430-A26DB6E4449F

P478

Q36708370-A5CC9AC4-A8D8-4B95-AA25-2CACBE1DFB1D

P577

Q36708370-88832BB2-DF43-4DBE-834D-58FA65ACC2B7

P5875

Q36708370-D338F5FB-9C58-4273-AE56-2CEB6ED8E18D

P698

Q36708370-A6BDB2EC-808F-4DE6-8826-90631D410EE9

P356

J.1365-2133.2006.07602.X

P1433

British Journal of Dermatology

P1476

Severe psoriasis treated with a new macrolide: everolimus.

@en

P2093

Altomare A

http://www.w3.org/2001/XMLSchema#string

Altomare GF

http://www.w3.org/2001/XMLSchema#string

Colombo MD

http://www.w3.org/2001/XMLSchema#string

Franchi C

http://www.w3.org/2001/XMLSchema#string

Frigerio E

http://www.w3.org/2001/XMLSchema#string

Garutti C

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.

Review of the proliferation inhibitor everolimus.

Inflammatory skin diseases, T cells, and immune surveillance.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.

Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial.

P304

372-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2133.2006.07602.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

156

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6578142

http://www.w3.org/2001/XMLSchema#string

P698

17223881

http://www.w3.org/2001/XMLSchema#string